Poster with 5-years’ follow-up data presented at the 3rd World Arthroplasty Congress available
Episurf Medical (Nasdaq: EPIS B) today announces that the poster presentation “Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years” by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, et al. which was presented at the 3rd World Arthroplasty Congress, is now available through Episurf Medical’s website. The poster presentation focuses on clinical results from the use of the Episealer® knee implant with a follow-up of up to 5 years (15 patients with 5 years’ results). The poster concludes that “This alternative (Episealer®) can avoid early unicompartmental or total knee arthroplasty while maintaining the biomechanics of articulation and replacing chondral defects”.
“Positive 5-years’ results is a tremendous achievement. However, we are trying to be cautious as we look forward to seeing 5-years results published and in larger cohorts. That said, this is the second study from which we have seen strong preliminary results of up to 5-years, which is very comforting,” says Pål Ryfors, CEO Episurf Medical.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
[HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
[HtmlTitle:protected] => <h1 style="line-height:120%;"><strong>Poster with 5-years’ follow-up data presented at the 3rd World Arthroplasty Congress available </strong></h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] =>
[Body:protected] => Episurf Medical (Nasdaq: EPIS B) today announces that the poster presentation "Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years” by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, et al. which was presented at the 3rd World Arthroplasty Congress, is now available through Episurf Medical’s website. The poster presentation focuses on clinical results from the use of the Episealer® knee implant with a follow-up of up to 5 years (15 patients with 5 years’ results). The poster concludes that “This alternative (Episealer®) can avoid early unicompartmental or total knee arthroplasty while maintaining the biomechanics of articulation and replacing chondral defects”.
“Positive 5-years’ results is a tremendous achievement. However, we are trying to be cautious as we look forward to seeing 5-years results published and in larger cohorts. That said, this is the second study from which we have seen strong preliminary results of up to 5-years, which is very comforting,” says Pål Ryfors, CEO Episurf Medical.
[HtmlBody:protected] => <p style="margin-bottom: 11px; font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span><span><span style="color:#0e101a">Episurf Medical (Nasdaq: EPIS B) today announces that the poster presentation </span></span><em><span>"Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years”</span></em><span> by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, et al. which was presented at the 3rd World Arthroplasty Congress, is now available through Episurf Medical’s website. The poster presentation focuses on clinical results from the use of the Episealer® knee implant with a follow-up of up to 5 years (15 patients with 5 years’ results). The poster concludes that </span><em><span>“This alternative (Episealer®)</span></em> <em><span>can avoid early unicompartmental or total knee arthroplasty while maintaining the biomechanics of articulation and replacing chondral defects”</span></em><span>.</span></span></p>
<p style="margin-bottom: 11px; font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span><em><span><span style="color:#0e101a">“Positive 5-years’ results is a tremendous achievement. However, we are trying to be cautious as we look forward to seeing 5-years results published and in larger cohorts. That said, this is the second study from which we have seen strong preliminary results of up to 5-years, which is very comforting,”</span></span></em><span><span style="color:#0e101a"> says Pål Ryfors, CEO Episurf Medical. </span></span></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 12311
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
[Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
[2] => Episealer
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/3332057/1406243.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Poster with 5-years’ follow-up data presented at the 3rd World Arthroplasty Congress available
[Description:protected] => Poster with 5-years’ follow-up data presented at the 3rd World Arthroplasty Congress available
[CreateDate:protected] => 2021-04-23T06:30:16.573Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 3953769
[EncryptedId:protected] => 2E3CD13C33C2EDC7
[IsRegulatory:protected] =>
[PublishDate:protected] => 2021-04-23T06:30:00Z
[LastChangeDate:protected] => 2021-04-23T06:30:16.56Z
[Title:protected] => Poster with 5-years’ follow-up data presented at the 3rd World Arthroplasty Congress available
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/poster-with-5-years--follow-up-data-presented-at-the-3rd-world-arthroplasty-congress-available,c3332057
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)